Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of FCN-437c plus fulvestrant with or without goserelin in HR-positive, HER2-negative advanced breast cancer
CTR20213307Phase 3Active
- Sponsor
- Fochon Biosciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ongiciclib in breast cancer, sponsored by Fochon Biosciences. Started Jan 2022; status: active.
02
Drugs
ongiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20213307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213307.